title: New developments in the field of diffuse large cell lymphoma.
abstract: This update will focus on new developments which can impact the understanding and management of patients with DLCL. The latter disorder is mostly derived from B lymphocytes which can be further subdivided into those that originate from the germinal center versus those  that arise from non-germinal center areas in the lymph node. The differences between these two types will be discussed. The management of several new entities that relate to DLCL such as 'double hit lymphoma' and so called borderline entities will also be featured. New entities  such as breast implant associated anaplastic large cell lymphoma will be described.
authors.affiliation: Auxilio Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico 00927, USA. fcabanil@mdanderson.org
authors.forename: Fernando
authors.initials: F
authors.lastname: Cabanillas
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D018427:Breast Implants / Q000009:adverse effects; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000209:etiology / Q000473:pathology* / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib